Valsartan 160 mg/Amlodipine 5 mg Combination Therapy versus Amlodipine 10 mg in Hypertensive Patients with Inadequate Response to Amlodipine 5 mg MonotherapyValsartan/Amlodipine 160/5mg Combination therapy versus Amlodipine 10mg in hypertensive patients with inadequate response to amlodipine 5mg monotherapy
- Other Titles
- Valsartan/Amlodipine 160/5mg Combination therapy versus Amlodipine 10mg in hypertensive patients with inadequate response to amlodipine 5mg monotherapy
- Authors
- Sung, J[Sung, Jidong]; Jeong, JO[Jeong, Jin-Ok]; Kwon, SU[Kwon, Sung Uk]; Won, KH[Won, Kyung Heon]; Kim, BJ[Kim, Byung Jin]; Cho, BR[Cho, Byung Ryul]; Kim, MK[Kim, Myeong-Kon]; Lee, S[Lee, Sahng]; Kim, HJ[Kim, Hak Jin]; Lim, SH[Lim, Seong-Hoon]; Park, SW[Park, Seung Woo]; Park, JE[Park, Jeong Euy]
- Issue Date
- Mar-2016
- Publisher
- KOREAN SOC CARDIOLOGY
- Citation
- KOREAN CIRCULATION JOURNAL, v.46, no.2, pp.222 - 228
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- KOREAN CIRCULATION JOURNAL
- Volume
- 46
- Number
- 2
- Start Page
- 222
- End Page
- 228
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/37690
- DOI
- 10.4070/kcj.2016.46.2.222
- ISSN
- 1738-5520
- Abstract
- Background and Objectives: When monotherapy is inadequate for blood pressure control, the next step is either to continue monotherapy in increased doses or to add another antihypertensive agent. However, direct comparison of double-dose monotherapy versus combination therapy has rarely been done. The objective of this study is to compare 10 mg of amlodipine with an amlodipine/valsartan 5/160 mg combination in patients whose blood pressure control is inadequate with amlodipine 5 mg. Subjects and Methods: This study was conducted as a multicenter, open-label, randomized controlled trial. Men and women aged 20-80 who were diagnosed as having hypertension, who had been on amlodipine 5 mg monotherapy for at least 4 weeks, and whose daytime mean systolic blood pressure (SBP) >= 135 mmHg or diastolic blood pressure (DBP)>= 85 mmHg on 24-hour ambulatory blood pressure monitoring (ABPM) were randomized to amlodipine (A) 10 mg or amlodipine/valsartan (AV) 5/160 mg group. Follow-up 24-hour ABPM was done at 8 weeks after randomization. Results: Baseline clinical characteristics did not differ between the 2 groups. Ambulatory blood pressure reduction was significantly greater in the AV group compared with the A group (daytime mean SBP change: -14 +/- 11 vs. -9 +/- 9 mmHg, p<0.001, 24-hour mean SBP change: -13 +/- 10 vs. -8 +/- 8 mmHg, p<0.0001). Drug-related adverse events also did not differ significantly (A:AV, 6.5 vs. 4.5 %, p=0.56). Conclusion: Amlodipine/valsartan 5/160 mg combination was more efficacious than amlodipine 10 mg in hypertensive patients in whom monotherapy of amlodipine 5 mg had failed.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/37690)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.